Centene (CNC) Stock Analysis 2026 × 3.8x EV/EBITDA, P/B 0.94x, $18.8B Medicaid MCO, April 28 Earnings

Centene Corporation (NYSE: CNC) manages healthcare benefits for approximately 27–30 million members across Medicaid, CHIP, Medicare Advantage, and ACA marketplace plans. It is the largest Medicaid managed care organization (MCO) in the United States. It processes roughly $140 billion in annual revenue — almost entirely premium payments from state and federal Medicaid programs that pass through to healthcare providers.

At $38.17, the stock has fallen more than 58% from its 2022 peak of $92. It now trades at 3.8x EV/EBITDA, 0.94x book value, and 12.8x forward earnings — multiples that reflect a business at the intersection of three intersecting headwinds: post-pandemic Medicaid membership redeterminations, federal budget uncertainty around Medicaid funding, and a GAAP loss year from restructuring charges. Equity Rank assigns an Overall Score of 74.0, Combined Margin of Safety of +75.4%, and Risk Score of 48.8. With Q1 2026 earnings on April 28, the quarter will test whether the worst of the membership erosion is behind Centene.

CNC Quick-Snapshot (April 2026)

The Business: Medicaid MCO at Scale

Centene is a managed care organization — a private health insurance company that contracts with state governments to manage Medicaid and CHIP benefits. The economic model is straightforward:

1. States pay Centene a monthly capitation rate per member (a fixed per-member-per-month premium)
2. Centene assumes the insurance risk — it pays medical claims out of that premium
3. Centene earns the difference between the capitation premium and the total medical costs paid (net of administrative expenses)

The critical metric is the Medical Loss Ratio (MLR) — the percentage of premium revenue spent on medical costs. Centene targets an MLR in the range of 87–90%. At 10.5% gross margin, Centene retains approximately 10–13 cents of every dollar in premium revenue after paying providers. This is not a sign of a weak business — it is how managed care economics work. The scale makes the model profitable: 30 million members — $400/month premium = $144B revenue; 1% efficiency improvement = $1.44B in additional income.

Program mix:

• Medicaid (~65% of revenue): Government-sponsored coverage for low-income Americans. Centene is the #1 managed Medicaid plan by enrollment, operating in 29 states.
• ACA Marketplace (~25% of revenue): Subsidized individual insurance plans. Centene rebranded ACA plans under the Ambetter brand.
• Medicare Advantage (~10% of revenue): Managed Medicare for seniors. Growing segment but smaller.

Geographic diversity: Centene operates in all 50 states (Medicaid programs vary by state rules, population, and funding). This diversification reduces the risk of any single state policy change devastating the business.

The Discount Explained: Three Overlapping Headwinds

1. Medicaid Redeterminations (2023–2025 — largely complete)

During the COVID-19 pandemic, the federal government prohibited states from removing anyone from Medicaid. This "continuous enrollment" policy artificially inflated Medicaid enrollment by an estimated 15–20 million people nationally. Starting April 2023, states began the "redetermination" process — reviewing each member's eligibility and disenrolling those who no longer qualified.

Centene lost approximately 4–5 million members through redeterminations between mid-2023 and mid-2025. Each lost member represents ~$400/month in capitation revenue that disappears. This was the primary driver of the earnings decline from 2022–2024. By early 2026, the redetermination process is substantially complete in most states — the enrollment headwind is becoming a tailwind as natural Medicaid growth resumes.

2. GAAP Loss Year (Restructuring + Divestitures)

The −28.7% ROE reflects GAAP accounting losses from restructuring charges and divestitures — primarily the sale of Magellan Health, Centurion (correctional health), and other non-core segments Centene acquired during a prior expansion phase. These one-time GAAP charges do not represent operating business deterioration. The underlying managed care business remains cash-generative; the GAAP loss year is why the trailing PE is effectively zero.

The forward PE of 12.80x on forward EPS of ~$2.98 reflects the business's expected normalized earnings once restructuring is complete. This is the operative valuation metric.

3. Federal Medicaid Funding Risk (2026 Ongoing)

The most current and potentially serious risk: federal budget reconciliation in 2026. Republican-led proposals to convert federal Medicaid matching funds to block grants or per-capita caps would reduce the growth in federal Medicaid spending over time. While full block grants are politically difficult to pass, any reduction in federal matching rates would reduce state Medicaid budgets and ultimately compress Centene's capitation rates.

This risk is real but highly uncertain — Medicaid block grants have been proposed and defeated multiple times over 30 years because they are politically toxic (cutting health coverage for vulnerable populations). The market is pricing in meaningful probability of some Medicaid funding constraint, which is a contributor to the current discount.

Valuation: 3.8x EV/EBITDA vs. Peers at 10–13x

The most compelling valuation case for Centene is the EV/EBITDA multiple:

Centene at 3.79x EV/EBITDA trades at a 70% discount to UnitedHealth and a 58% discount to its most direct Medicaid peer, Molina Healthcare. Even if Centene deserves a permanent discount to UNH for its higher Medicaid concentration, execution risk, and governance history — a re-rating from 3.8x to even 6x EV/EBITDA would represent 58% upside to enterprise value.

Book value anchor: BVPS of ~$40.56 vs. price $38.17 = P/B of 0.94x. For a company generating $140B in revenue with hard assets (insurance licenses, IT infrastructure, provider contracts), trading below book is unusual. P/B of 1.0x (back to par) = $40.56 price (+6%). P/B of 1.3x (Molina's multiple) = $52.73 (+38%).

Forward PE at 12.80x: Reasonable but not extreme for healthcare. If forward EPS of $2.98 holds, and the market applies a normalized managed care PE of 15x, the implied price is $44.70 (+17%). At UNH's 20x forward PE, implied price would be $59.60 (+56%).

Screener Combined MoS: +75.4% reflects the blended consensus of multiple valuation methods — the model's view is that current pricing materially undervalues the business even under conservative assumptions.

April 28 Earnings: The Redetermination Recovery Test

Q1 2026 earnings on April 28 will be the first look at whether the post-redetermination recovery thesis is working. Key metrics to watch:

Total membership: Is Medicaid enrollment stabilizing or growing? Any net positive membership addition from natural Medicaid enrollment (economic softness typically increases Medicaid eligibility) is bullish.

Medical Loss Ratio (MLR): Did Q1 come in below or above the target range of 87–90%? A high MLR (above 90%) signals either underprice capitation rates or unexpected utilization increases — both margin negative. An MLR in-range confirms pricing discipline.

Forward EPS guidance: Management's forward EPS guidance is the single most important number in the report. The screener's implied forward EPS of ~$2.98 needs management confirmation or revision. Any guide-up is significantly bullish given the depressed multiple.

ACA marketplace performance: 2026 is the first year without extended ACA subsidies (the enhanced subsidies from the Inflation Reduction Act expired). How did Centene's Ambetter marketplace membership hold up? Any enrollment deterioration in ACA signals premium affordability stress.

Medicaid rate updates: Many states set Medicaid capitation rates annually. Any disclosure of 2026 rate increases (typically announced Q4–Q1) with margin-positive terms is a positive catalyst.

Equity Rank Screener Profile

The AI Displacement Score of 30 (low) is notable. Healthcare administration is not easily disrupted by AI — state contracts require regulatory compliance, actuarial expertise, and deep government relationships that are not replicable through software automation. Centene's core Medicaid business benefits from some AI assistance (prior authorization automation, fraud detection) but is not at risk of being displaced by AI.

The Risk Score of 48.8 (moderate) is appropriate for a company with:

• Significant regulatory dependency (Medicaid contracts can be lost to competitors)
• Political risk (federal Medicaid funding policy changes)
• A GAAP loss year reducing earnings visibility
• But also: Beta 0.587 (low market correlation), essential service (healthcare), and geographic diversification

Bear and Bull Cases

Bull case: The Medicaid redetermination cycle is over. Membership stabilizes and grows as the economy softens and more families qualify for Medicaid. Federal block grant proposals fail in Congress (as they have historically). Forward EPS of $3 is achieved. Managed care multiples re-rate from 3.8x EV/EBITDA toward 7–9x (well below peer averages). Implied model value $55–65 range.

Bear case: Federal budget reconciliation passes significant Medicaid per-capita caps, reducing state budgets and forcing capitation rate reductions. MLR unexpectedly rises above 90% due to increased post-pandemic utilization. ACA marketplace enrollment falls as subsidies decline. Forward EPS misses $2.98 target. Multiple stays compressed. Stock tests $30 support.

Calculator Tools: Model CNC Under Your Assumptions

The PE Ratio Calculator is the key tool for CNC given the absence of trailing earnings. Enter forward EPS of $2.98 and vary the PE multiple from 10x (deep discount) to 18x (normalized managed care) to see the fair value range of $29.80–$53.64. This exercise makes clear that the current price of $38.17 is only justified if PE stays permanently compressed below 13x.

The EV/EBITDA Calculator allows you to model Centene's enterprise value under different EV/EBITDA assumptions. At 3.79x and market cap $18.8B, the enterprise value is approximately $25–30B. Enter EBITDA and vary the multiple from 4x (current) to 9x (Molina peer) to compute the implied equity value per share — the gap to peers is the clearest way to visualize the discount.

The DCF Calculator models Centene's healthcare cash flow durability. Start with $145B revenue at 3% organic growth, 1.5% FCF margin (reflecting tight managed care economics), and 9% discount rate — then vary the FCF margin between 1% and 3% (representing MLR efficiency improvements from operational leverage) to see how sensitive intrinsic value is to margin improvement.

The Equity Rank screener shows Centene's full profile alongside all 800 large-cap stocks — Overall Score 74.0, Combined MoS +75.4%, Risk Score 48.8, SAVE Score 68.8, EV/EBITDA 3.79x, P/B 0.94x, Beta 0.587, AI Displacement 30 — updated weekly.

This article is for informational and educational purposes only. It does not constitute financial advice or a recommendation to purchase or sell Centene Corporation (CNC) shares or any other security. All scores, margin of safety estimates, and valuation outputs are model-based and subject to significant estimation uncertainty. The 75.4% combined margin of safety includes valuation methods that apply Healthcare sector median multiples to Centene; managed care companies historically trade at discounts to broader Healthcare sector averages due to thin margins, regulatory dependency, and political risk — sector-median multiples may overstate Centene's fair value. The trailing P/E is effectively zero due to GAAP losses from restructuring charges and divestitures; the trailing ROE of −28.7% reflects these non-recurring items, not ongoing operational deterioration. Forward EPS of approximately $2.98 is an implied estimate based on forward PE ratio and current price; actual analyst consensus figures should be verified independently. Centene's revenue growth of +23.2% includes acquisition and ACA membership contributions and does not represent organic managed care growth. Gross margin of 10.5% is typical for managed care (reflecting the Medical Loss Ratio structure) and is not directly comparable to product or software gross margins. Federal Medicaid policy is subject to Congressional action, and proposals to convert Medicaid to block grants or per-capita caps — if enacted — could materially reduce Centene's revenue and earnings. ACA marketplace subsidies and enrollment may change significantly in 2026 and beyond, affecting Centene's non-Medicaid revenue. Medicaid contracts are competitively bid and can be lost to competitor MCOs at rebid; loss of a major state contract would have a material negative impact. Beta of 0.587 reflects historical market correlation but does not protect against company-specific regulatory or earnings risk. Revenue growth and membership figures are affected by state redetermination timelines which vary by state and are not fully within Centene's control. Past financial performance does not guarantee future results. All investments involve risk, including potential loss of principal. Equity Rank is not a registered investment adviser. Always conduct your own due diligence and consult a qualified financial adviser before making investment decisions.